Omeprazole and Kidney Damage: What the Evidence Shows
Updated: 4 hours ago
The short answer
For most people a proton pump inhibitor does very little to the kidneys, and for a smaller group who take one every day for years it does something real. Across the large cohorts, people on these drugs developed new chronic kidney disease at a rate roughly 24 to 50 percent higher than people who did not, which over about a decade works out to close to 12 people in 100 rather than 8 or 9. Every one of those studies is observational, so the pill has not been shown to cause the damage: people who stay on daily acid suppression for years also tend to be older, heavier, and carrying more kidney risk to begin with. The risk worth acting on is concentrated in silent, indefinite, high-dose use by people who already have kidney disease, and the fix is usually a planned review rather than stopping the drug.
What we cover
Why the same acid pill can be close to harmless for one person and a real risk for another.
What the most-quoted study found across two large cohorts: new chronic kidney disease was 24 to 50 percent more common in proton pump inhibitor users. (JAMA Internal Medicine, 2016)
What a pooled analysis of 12 studies and about 700,000 people found, and how users compared against people on older H2 blockers like famotidine. (Biomedicines, 2024)
What that higher rate looks like in absolute terms over roughly ten years, about 12 in 100 against 8 or 9 in 100. (JAMA Internal Medicine, 2016)
Why confounding by indication matters here, and why causation is still not established. (Arquivos de Gastroenterologia, 2022)
Acute interstitial nephritis, the one recognized way these drugs can directly injure a kidney, and the symptoms that should prompt a call.
How the signal tracks with dose and duration, with twice-daily dosing carrying more risk than once-daily. (JAMA Internal Medicine, 2016)
Who genuinely needs to stay on the drug, and why stopping abruptly causes acid rebound rather than proving you needed it. (Arquivos de Gastroenterologia, 2022)
Timestamps
00:00 Two true things about heartburn pills
00:52 Meet Dr. Sean Hashmi
01:07 Why this matters at this scale
01:53 The 2016 JAMA study everyone quotes
02:35 The 2024 meta-analysis of 700,000 people
03:10 What a 30% higher risk means in real numbers
04:15 Write down your pill name, dose, and duration
04:32 Why these studies can't prove causation
05:31 The umbrella and the rain, explained
05:52 The comparison that keeps this signal alive
06:29 Where I draw the line as a nephrologist
07:02 The one real risk: acute interstitial nephritis
08:05 The part I held back: dose times time
09:35 Do you actually need this pill?
10:41 The "low stomach acid" myth, debunked
11:20 The smarter way to come off a PPI
13:49 The one thing to do this week
References
Lazarus B, Chen Y, Wilson FP, et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Internal Medicine. 2016;176(2):238-246. PMID 26752337. https://doi.org/10.1001/jamainternmed.2015.7193 (observational cohort study with replication cohort).
In the ARIC cohort, proton pump inhibitor use was associated with incident chronic kidney disease at an adjusted hazard ratio of 1.50 (95% CI 1.14 to 1.96), and 1.39 (1.01 to 1.91) when compared against H2 blocker users; a replication cohort of almost a quarter of a million patients gave 1.24 (1.20 to 1.28). Risk was graded by dose, 1.46 (1.28 to 1.67) for twice-daily against 1.15 (1.09 to 1.21) for once-daily. Estimated 10-year absolute risk was 11.8 percent in users against 8.5 percent in non-users. This paper is also where the acute interstitial nephritis link is set out.
Ang SP, Chia JE, Valladares C, et al. Association between Proton Pump Inhibitor Use and Risk of Incident Chronic Kidney Disease: Systematic Review and Meta-Analysis. Biomedicines. 2024;12(7):1414. PMID 39061988. https://doi.org/10.3390/biomedicines12071414 (systematic review and meta-analysis of observational studies).
Pooling 12 studies and 700,125 participants, proton pump inhibitor use carried a hazard ratio of 1.26 (95% CI 1.16 to 1.38) for incident chronic kidney disease against non-use, and 1.34 (1.13 to 1.59) against H2 blockers.
Chinzon D, Domingues G, Tosetto N, Perrotti M. Safety of Long-Term Proton Pump Inhibitors: Facts and Myths. Arquivos de Gastroenterologia. 2022;59(2):219-225. PMID 35830032. https://doi.org/10.1590/S0004-2803.202202000-40 (narrative review).
The kidney association is strongest in older people, in long-term and high-dose use, and in people who already have kidney disease, and the authors state plainly that a causal link is still subject to validation. The same review describes acid rebound on abrupt discontinuation and sets the goal as rational use at the lowest effective dose for the shortest necessary duration.
One study explained in plain language every week, with sources attached, plus the free kidney health guide: https://guides.selfprinciple.org/kidney
This content is for educational purposes only and is not medical advice. Always consult your healthcare provider for individual care. The views expressed are Dr. Sean Hashmi's own and do not represent his employer.
Never start, stop, or change the dose of any prescription medication without consulting your physician.
Comments